American Diversified Holdings said today it inked a deal to acquire Houston-based Brazos Biomedical for an undisclosed amount.
Brazos Biomedical is developing the Auracis device, which is designed to treat headache pain through the use of transcutaneous electrical nerve stimulation.
“Auracis has tremendous potential to alleviate suffering in people who suffer from migraine headaches. Our proprietary technology most closely mimics the most effective treatment for migraine at a fraction of the cost and without the risks of surgical implants,” David Foster of Brazos Biomedical said in a press release.
The device includes a number of electrodes designed to be placed at key points on the head and neck to stimulate cranial nerves and mute pain signals typical to Migraine headaches.
“The acquisition of Brazos is a very significant milestone for the Company. The Auracis device has the potential to transform an unmet medical need for migraine sufferers using a base technology (TENS) that has been used clinically for over twenty years and is generally regarded as safe. The acquisition is designed to accelerate product development and to provide resources for future product innovation and development,” ADHC commented in a prepared statement.
